Sponsor content

Shionogi’s growing anti-infectives portfolio

With core competencies in small-molecule drug design and synthesis, Shionogi continues to achieve success in and expand its infectious disease portfolio of both antibacterials and antivirals, many of which are home-grown products.

Go to the profile of Shionogi
Jun 06, 2018
0
0
Upvote 0 Comment
Page of
Go to the profile of Shionogi

Shionogi

Shionogi & Co., Ltd. is a Japanese major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” Shionogi Inc., the U.S. based subsidiary of Shionogi & Co., Ltd., continues this focus on the development and commercialization of high quality medicines that protect the health and well-being of the patients we serve. The company currently markets products in several therapeutic areas including anti-infectives, pain, cardiovascular diseases and gastroenterology. Our pipeline is focused on infectious disease, pain, CNS and oncology. For more details on Shionogi Inc., visit www.shionogi.com. For more information on Shionogi & Co., Ltd., visit www.shionogi.co.jp/en.

No comments yet.